Navigation Links
The Leukemia & Lymphoma Society Available to Comment on Findings Presented at American Society of Hematology Conference
Date:12/2/2009

WHITE PLAINS, N.Y., Dec. 2 /PRNewswire-USNewswire/ -- Researchers from around the world will present their findings in blood cancer research at the annual American Society of Hematology (ASH) conference in New Orleans December 4-8, 2009.

Throughout the ASH conference, The Leukemia & Lymphoma Society (LLS) experts, including Chief Medical Officer Barton Kamen, M.D., Ph.D., Senior Vice President of Patient Services Hildy Dillon, and Vice President, Research Communications Deborah Banker, will be available to comment on any research news to emerge from the meeting.

To arrange interviews in advance or during the conference, please contact Andrea Greif at (914) 821-8958 or (914) 772-3027 (cell).

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

SOURCE The Leukemia & Lymphoma Society


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. Study finds heart failure is rare among leukemia patients on imatinib
3. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. Novel strategy under study for aggressive leukemia
7. Drug has ability to cure type of leukemia
8. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
9. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
11. St. Jude Finds Anti-Leukemia Drug Increases Patient Fatigue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 -- vRad ( Virtual Radiologic ), the nation’s ... Arlene Sussman, MD, a highly regarded breast imaging and ... explore how telemedicine best practices allow for the access ... virtually anywhere. Click here to register for ... 4, 2015 at 1:00 pm CT. , Hospitals must ...
(Date:3/3/2015)... Introducing 3D Digital Technologies to their ... leader in Digital Dentistry. Acute precision in ... replicas, leaving no room for error during the ... are able to significantly reduce “chair time” and ... quality while reducing labor and material costs proving ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 In a ... Morning Edition, science correspondent Shankar Vedantam shared ... Pennsylvania about the drastic decrease in hand-hygiene compliance that occurs ... that the problem could be solved in part by alerts ... hygiene when they enter and exit a patient’s room. ...
(Date:3/3/2015)... 2015) (PRWEB) March 03, 2015 President/CEO ... innovator in the travel industry for the past 10 ... plan. To fulfill his vision for the future of ... fun, exciting and well-compensated positions as travel sales specialists ... sales center planned for the Boynton Beach, Florida area. ...
(Date:3/3/2015)... Retrofit , the comprehensive weight management ... today announces the appointment of its new chief technology ... Mary Pigatti has recruited technology, healthcare and people ... the fast-growing company, which was recently named one of ... , “Retrofit is thrilled to announce this new acquisition ...
Breaking Medicine News(10 mins):Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 2Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 3Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 4Health News:Iverson Dental Labs Introduces 3D Digital Dental Technology for Superior Products 2Health News:Iverson Dental Labs Introduces 3D Digital Dental Technology for Superior Products 3Health News:BIOVIGIL Hygiene Technologies Answers Call for Hand Hygiene Alerts on Badges 2Health News:BIOVIGIL Hygiene Technologies Answers Call for Hand Hygiene Alerts on Badges 3Health News:First Class Vacations, Inc. Expansion Plan Creates 400 Jobs In South Florida 2Health News:First Class Vacations, Inc. Expansion Plan Creates 400 Jobs In South Florida 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 2Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 3Health News:Retrofit Signals Growth: Corporate Weight Management Company Announces Talent Acquisitions 4
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Sept. ... report released earlier this week, a new study shows that men ... not really need future screening. Conversely, men with a high ... should be monitored and have an increased risk of developing the ...
... Adults with congenital heart disease are more likely ... heart-related symptoms and sensations if their parents ... Lephuong Ong from Orion Health Services in Vancouver, ... University in Toronto, Canada, suggest that health care ...
... -- Oregon Health & Science University,s Markus Grompe, M.D., ... participate in the prestigious Beta Cell Biology Consortium (BCBC). ... and Kidney Diseases, the consortium,s long-term goal is to ... 1 diabetes patients. "The goal of our work ...
... , TUESDAY Sept. 14 (HealthDay News) -- A new antibiotic-resistant ... a handful of people in North America, with three of ... Tuesday. But the bacterium -- designated New Delhi ... bacterium that,s been present in the United States for many ...
... well known that exposure to radiation has multiple harmful effects ... been unclear to what extent such exposure increases a person,s ... large-scale study of the relationship between radiation dose and risk ... Nagasaki, Japan reveals a similar risk in the development of ...
... Arnhem, 15 September 2010 A recent TNS NIPO survey, on ... Association of Urology (EAU), showed that almost four out of 10 ... from urinary complaints. The same number of men also said in ... cancer. The TNS NIPO survey also indicated that a ...
Cached Medicine News:Health News:Men With Low PSA at 60 Might Not Need Further Screening 2Health News:Men With Low PSA at 60 Might Not Need Further Screening 3Health News:Overprotective parents may impact heart anxiety in adults with congenital heart conditions 2Health News:OHSU research team joins elite consortium dedicated to curing type 1 diabetes 2Health News:New Drug-Resistant 'Superbug' Reaches U.S. Shores 2Health News:New Drug-Resistant 'Superbug' Reaches U.S. Shores 3Health News:Radiation exposure poses similar risk of first and second cancers in atomic bomb survivors 2
(Date:3/3/2015)... JACKSONVILLE, Fla. , March 3, 2015 /PRNewswire/ ... is pleased to announce the hiring of ... Sales to lead business development efforts and build ... years of experience in software development, sales, and ... of enterprise software applications. iTraycer is a comprehensive ...
(Date:3/3/2015)... LOUISVILLE, Ky. , March 3, 2015 ... Louisville,s greatest leaders in aesthetics. In ... successful Brownsboro Plastic and Hand Surgery practice, Dr. Cummins ... Louisville Tattoo Removal clinic . Dr. Cummins performs ... "I founded Louisville Tattoo Removal in order ...
(Date:3/3/2015)... March 3, 2015   ... 240 patients respectively Publications in peer reviewed ... Clinical Gastroenterology highlight diagnostic value of confocal laser ... China and across Asia ... (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal ...
Breaking Medicine Technology:Medical Tracking Solutions, Inc. Hires New SVP, Sales 2Surgeon Owned And Operated Louisville Tattoo Removal Offers Astanza Duality Laser Treatments 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 3Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 4
... from a pivotal trial suggests that ofatumumab has activity ... , , , ... Genmab A/S (OMX: GEN) announced today positive results from ... in the treatment of refractory chronic lymphocytic leukemia (CLL). ...
... HUNTINGTON BEACH, California and AMSTERDAM, December 8 ,Agendia, ... announced that,leading Agendia and the Netherlands Cancer Institute ... 2008 San Antonio Breast Cancer Symposium,(SABCS) and Agendia ... in Individualized Breast Cancer Therapy symposium. The San ...
Cached Medicine Technology:Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 2Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 3Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 4Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 5Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 6Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 8Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 9Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 2Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 3Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 4
Complete product line for typing all classical HLA loci including A, B, C DRA, DRB1, DRB3, DRB4, DRB5, DQA, DQB1, DPA1, and DPB1....
... Our Class II Direct to High Res SSP ... with a single tray. Locus specific typing on a ... time. , Straight from genomic DNA to high ... , Allele level typing with a single tray , ...
... Our Class I Direct to High Res SSP ... with a single tray. Locus specific typing on a ... time. , Straight from genomic DNA to high ... , Allele level typing with a single tray , ...
... High Res SSP kits provide high resolution typing of ... typing on a single tray reduces QC and testing ... DNA to high resolution results, no need for initial ... single tray , Unique reaction pattern for most common ...
Medicine Products: